MRI activity and extended interval of Natalizumab dosing regimen : a multicentre Italian study
Copyright © 2021 Elsevier B.V. All rights reserved..
BACKGROUND: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID).
METHODS: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: <5 weeks, SID; ≥5 weeks, EID.
RESULTS: One hundred and eighty-seven patients were in the SID group (MDI = 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84-7.70) vs 4.71% (95% CI:0.16-9.25%) [p = 0.89] and 8.50% (95% CI:4.05-12.95) vs 6.55% (95% CI:2.11-11.00%) [p = 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up.
CONCLUSION: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:424 |
---|---|
Enthalten in: |
Journal of the neurological sciences - 424(2021) vom: 15. Mai, Seite 117385 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
De Mercanti, Stefania Federica [VerfasserIn] |
---|
Links: |
---|
Themen: |
Efficacy |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jns.2021.117385 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM323266347 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323266347 | ||
003 | DE-627 | ||
005 | 20231225183820.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jns.2021.117385 |2 doi | |
028 | 5 | 2 | |a pubmed24n1077.xml |
035 | |a (DE-627)NLM323266347 | ||
035 | |a (NLM)33770708 | ||
035 | |a (PII)S0022-510X(21)00078-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a De Mercanti, Stefania Federica |e verfasserin |4 aut | |
245 | 1 | 0 | |a MRI activity and extended interval of Natalizumab dosing regimen |b a multicentre Italian study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 31.05.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND: To minimize the risk of Progressive Multifocal Leukoencephalopathy and rebound in JCV-positive multiple sclerosis (MS) patients after 24 natalizumab doses, it has been proposed to extend the administrations interval. The objective is to evaluate the EID efficacy on MRI activity compared with the standard interval dosing (SID) | ||
520 | |a METHODS: Observational, multicentre, retrospective cohort study, starting from the 24th natalizumab infusion to the loss of follow-up or 2 years after baseline. Three hundred and sixteen patients were enrolled. The median dose interval (MDI) following the 24th infusion was 5 weeks, with a bimodal distribution (modes at 4 and 6 weeks). Patients were grouped into 2 categories according to the mean number of weeks between doses: <5 weeks, SID; ≥5 weeks, EID | ||
520 | |a RESULTS: One hundred and eighty-seven patients were in the SID group (MDI = 4.5 weeks) and 129 in the EID group (MDI 6.1 weeks). The risk to develop active lesions on MRI is similar in SID and EID groups during the 6 and 12 months after the 24th natalizumab infusion, respectively 4.27% (95% CI:0.84-7.70) vs 4.71% (95% CI:0.16-9.25%) [p = 0.89] and 8.50% (95% CI:4.05-12.95) vs 6.55% (95% CI:2.11-11.00%) [p = 0.56]. The EID regimen does not appear to increase the occurrence of MRI activity during follow-up | ||
520 | |a CONCLUSION: There is no evidence of the reduced efficacy of natalizumab in an EID setting regarding the MRI activity. This observation supports the need for a bigger randomized study to assess the need to change the standard of the natalizumab dosing schedule, to better manage JCV-positive patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Observational Study | |
650 | 4 | |a Efficacy | |
650 | 4 | |a Extended dose | |
650 | 4 | |a Magnetic resonance imaging | |
650 | 4 | |a Multiple sclerosis | |
650 | 4 | |a Natalizumab | |
650 | 7 | |a Immunologic Factors |2 NLM | |
650 | 7 | |a Natalizumab |2 NLM | |
700 | 1 | |a Signori, Alessio |e verfasserin |4 aut | |
700 | 1 | |a Cordioli, Cinzia |e verfasserin |4 aut | |
700 | 1 | |a Signoriello, Elisabetta |e verfasserin |4 aut | |
700 | 1 | |a Lus, Giacomo |e verfasserin |4 aut | |
700 | 1 | |a Bonavita, Simona |e verfasserin |4 aut | |
700 | 1 | |a Abbadessa, Gianmarco |e verfasserin |4 aut | |
700 | 1 | |a Lavorgna, Luigi |e verfasserin |4 aut | |
700 | 1 | |a Maniscalco, Giorgia Teresa |e verfasserin |4 aut | |
700 | 1 | |a Curti, Erica |e verfasserin |4 aut | |
700 | 1 | |a Lorefice, Lorena |e verfasserin |4 aut | |
700 | 1 | |a Cocco, Eleonora |e verfasserin |4 aut | |
700 | 1 | |a Nociti, Viviana |e verfasserin |4 aut | |
700 | 1 | |a Mirabella, Massimiliano |e verfasserin |4 aut | |
700 | 1 | |a Baroncini, Damiano |e verfasserin |4 aut | |
700 | 1 | |a Mataluni, Giorgia |e verfasserin |4 aut | |
700 | 1 | |a Landi, Doriana |e verfasserin |4 aut | |
700 | 1 | |a Petruzzo, Martina |e verfasserin |4 aut | |
700 | 1 | |a Lanzillo, Roberta |e verfasserin |4 aut | |
700 | 1 | |a Gandoglia, Ilaria |e verfasserin |4 aut | |
700 | 1 | |a Laroni, Alice |e verfasserin |4 aut | |
700 | 1 | |a Frangiamore, Rita |e verfasserin |4 aut | |
700 | 1 | |a Sartori, Arianna |e verfasserin |4 aut | |
700 | 1 | |a Cavalla, Paola |e verfasserin |4 aut | |
700 | 1 | |a Costantini, Gianfranco |e verfasserin |4 aut | |
700 | 1 | |a Capra, Ruggero |e verfasserin |4 aut | |
700 | 1 | |a Sormani, Maria Pia |e verfasserin |4 aut | |
700 | 1 | |a Clerico, Marinella |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 424(2021) vom: 15. Mai, Seite 117385 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
773 | 1 | 8 | |g volume:424 |g year:2021 |g day:15 |g month:05 |g pages:117385 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2021.117385 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 424 |j 2021 |b 15 |c 05 |h 117385 |